期刊文献+

他汀类药物治疗慢性肾脏病的临床疗效 被引量:1

Clinical efficacy of statins in the treatment of chronic kidney disease
下载PDF
导出
摘要 目的探究他汀类药物治疗慢性肾脏病的临床疗效。方法 70例慢性肾脏病患者,采用随机分配方法分为实验组与参照组,各35例。参照组给予常规治疗,实验组在参照组基础上联合给予他汀类药物治疗。比较两组患者临床资料(平均体质量、平均病程)、治疗前后肾功能指标(血尿素氮、尿白蛋白排泄率、血清肌酐)及生活质量评分。结果两组患者平均体质量、平均病程比较,差异无统计学意义(P>0.05)。治疗后,实验组患者血尿素氮、尿白蛋白排泄率、血清肌酐分别为(9.02±1.75)mmol/L、(98.12±2.37)mg/24 h、(120.31±12.15)μmol/L,均优于参照组的(11.35±2.02)mmol/L、(131.12±6.24)mg/24 h、(150.31±15.03)μmol/L,差异有统计学意义(P<0.05)。治疗后,实验组患者生活质量评分显著高于参照组,差异有统计学意义(P<0.05)。结论他汀类药物用于治疗慢性肾脏病疗效显著,不仅可有效改善患者肾功能情况,并在一定程度上提高患者的生活质量,值得临床推广应用。 Objective To investigate the clinical efficacy of statins in the treatment of chronic kidney disease.Methods A total of 70 patients with chronic kidney disease were randomly divided into experimental group and control group,with 35 cases in each group.The control group received conventional therapy,and the control group received statins on the basis of the control group.Comparison were made on clinical data(mean body mass,mean course of disease),renal function index(blood urea nitrogen,urinary albumin excretion rate,serum creatinine)and quality of life score before and after treatment between the two groups.Results Both groups had no statistically significant difference in mean body mass and mean course of disease(P>0.05).After treatment,the experimental group had better blood urea nitrogen,urinary albumin excretion rate,serum creatinine respectively as(9.02±1.75)mmol/L,(98.12±2.37)mg/24 h and(120.31±12.15)μmol/L than(11.35±2.02)mmol/L,(131.12±6.24)mg/24 h and(150.31±15.03)μmol/L in the control group,and their difference was statistically significant(P<0.05).After treatment,the experimental group had significantly higher quality of life score than the control group,and the difference was statistically significant(P<0.05).Conclusion Statins are effective in the treatment of chronic kidney disease.They can not only improve the renal function of patients,but also improve the quality of life of patients to a certain extent.It is worthy of clinical promotion and application.
作者 刘波 LIU Bo(General Consulting Room,Liaoning Fushun Petrochemical General Hospital,Fushun 113006,China)
出处 《中国实用医药》 2019年第5期106-107,共2页 China Practical Medicine
关键词 慢性肾脏病 他汀类药物 肾功能 生活质量 Chronic kidney disease Statins Renal function Quality of life
  • 相关文献

参考文献6

二级参考文献37

  • 1Gansevoort RT, Correa - Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk : epidemiology, mechanisms, and prevention [J]. Lancet, 2013, 382 (9889): 339-352.
  • 2Pinkau T, Hilgers KF, Veelken R, et al. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? [J]. J Am Soc Nephrol, 2004, 15 (3): 517 -523.
  • 3National Kidney Foundation. KDIGO clinical practice guideline for lipid management in chronic kidney disease [ J ]. Kidney Int Suppl, 2013, 3 (3): 259-305.
  • 4Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States [ Jl. JAMA, 2007, 298 (17) : 2038 - 2047.
  • 5Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross- sectional survey [ J]. Lancet, 2012, 379 (9818): 815-822.
  • 6Mihos CG, Santana O. Pleiotropie effects of the HMG-CoA reductase inhibitors [J]- IntJGenMed, 2011, 4:261-271.
  • 7Mason JC. The statins - therapeutic diversity in renal disease? [ J ]. Curr Opin Nephrol Hypertens, 2005, 14 (1) : 17 -24.
  • 8Pasternak RC, Smith SC Jr, Bairey - Merz CN, et al. ACC/AHA/ NHLB1 clinical advisory" on the use and safety of statins [ J ]. J Am Coil Cardiol, 2002, 40 (3): 567-572.
  • 9Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions [ J]. Circulation, 2004, 109 (23 Suool I) : Ⅲ50 -57.
  • 10Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta analysis of randomised statin trials [J]. Lancet, 2010, 375 (9716): 735-742.

共引文献32

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部